Ariana Pelosci

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

The primary end point of ORR was met in the CAR-like T-cell arm for patients with gastric/GEJ cancer.

Results from arm A of a phase 1/2 trial showed improved efficacy with multi-antigen targeted T cells plus frontline chemotherapy.

Investigators assessed recurrence rates between axillary lymph node dissection recipients after neoadjuvant chemotherapy vs nonrecipients.

An investigational new drug application for ALA-101 has been submitted to the FDA for the treatment of CD19-positive non-Hodgkin lymphoma and leukemia.

In patients with cancer, there was an increased risk of cardiovascular death vs those who did not have cancer (HR, 2.46).

The approval of narsoplimab by the FDA may now prevent fatal complications from stem cell transplants.

VCU Massey Cancer Center is utilizing L-Dex bioimpedance spectroscopy to move toward a preventative model for lymphedema.

The approval of durvalumab plus FLOT for patients with resectable gastric/GEJ cancer cements itself as a new standard of care in the space.

Numerous clinicians spoke about breaking news, clinical trial updates, and the evolution of standard-of-care treatment throughout 2025.

Michelle Riba, MD, discusses the evolution of distress screening in oncology and the move toward a collaborative care model to integrate psychosocial support into clinical practice.

Daniel C. McFarland, DO; and Charles Kamen, PhD, MPH, discuss the unique challenges that sexual and gender minority groups experience in cancer care.

Moving the needle in cancer research was an important focus for the journal ONCOLOGY in 2025.

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

A label for imlunestrant/abemaciclib in ER+/HER2– advanced breast cancer with ESR1 mutations will be sought.

The 1-year EFS with CART19 was 90% among patients with B-ALL who had 1 or more CNS relapses.

Sunil Dutta, MD, discusses how whole-breast radiation or systemic therapy is responsible for controlling low-volume disease.

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

The primary end point of PFS was not statistically significant with sacituzumab govitecan vs chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.

Ziftomenib given at 600 mg in combination with venetoclax/azacitidine produced high response rates in NPM1-mutated AML.

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.